Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 6/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143625 | 0.87 | MAP4K1 (0.35) | KIF18AMAP4K1PTGER1GRM5FASN | |
| SCHEMBL21143596 | 0.87 | KIF18A (0.33) | KIF18AMAP4K1PTGER1GRM5FASN | |
| SCHEMBL19686613 | 0.83 | IDH1 (0.43) | IDH1 | |
| SCHEMBL21144188 | 0.77 | IDH1 (0.33) | IDH1 | |
| SCHEMBL19687205 | 0.75 | IDH1 (0.32) | IDH1 | |
| SCHEMBL21143704 | 0.74 | ADORA2A (0.41) | — | |
| SCHEMBL21143690 | 0.73 | ADORA2A (0.43) | — | |
| SCHEMBL21144226 | 0.73 | ADORA2A (0.41) | — | |
| SCHEMBL19686328 | 0.70 | IDH1 (0.40) | KIF18AIDH1 | |
| SCHEMBL19686818 | 0.67 | IDH1 (0.47) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KIF18A 691/4885MAP4K1 343/4885PTGER1 762/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KIF18A 691/4885MAP4K1 343/4885PTGER1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.